Replies to post #7840 on BioCurex, Inc.(fka BOCX)

[Headache]

In my view, it should be regarded as irrelevant. It's just a change of ownership, and while the new owners would certainly scrutinize all existing licensing agreements, they would have no greater reason to return the Biocurex license than the existing owners do. If the technology is strong, we should be fine.

That said, I would expect the existence of a buyer for Abbott Diagnostics to make the existing owner want to hasten development of a RECAF product in order to make the unit more attractive and command a better selling price.

[Gold Seeker]

IMO, GE would not toss out any projects but making commitments to the project during the sale would have to be discussed between both buyer and seller. GE would also not be buying it and then tossing out tests. If anything, they would want to speed commitment but it will slow decisions during the sale process. How long it takes depends upon government regulating bodies. The Pfizer consumer sale took six months.